Abstract Purpose: To analyze the expression of complement delay-accelerating factor (CD55) in nasopharyngeal carcinoma and its correlation with clinicopathologic features, including survival rate.
Nasopharyngeal carcinoma (NPC) is a common Epstein Barr Virus (EBV)-associated cancer with remarkable geographic and racial distributions worldwide [1] . It is highly prevalent in South China where its annual incidence rate is 25-50 cases per 100,000 populations [2] . NPC is a particular type of squamous carcinoma of head and neck. A recent study reported that the etiology of NPC includes viral, genetic, and environmental factors [3] . e primary anatomical site of tumor growth is located in a cryptic area and the disease is usually asymptomatic at early stages. Most NPCs are undi erentiated or poorly di erentiated with the following characteristics: fast growth and a great tendency to invade adjacent regions as well as metastasize to regional lymph nodes and distant organs [4] . e molecular mechanism of the development and progression of NPC is still poorly understood; therefore, it is of great interest to nd both e ective biomarkers for early diagnosis of as well as therapeutic targets for this malignancy.
CD55 (complement delay-accelerating factor; or decayaccelerating factor, DAF) is a glycosylphosphatidylinositolanchored protein that protects cells from complementmediated attack [5] . It was described for the rst time in 1969 as an erythrocyte surface protein that regulated complement system activation [6] . CD55 is present on all cells that are exposed to complement, including red blood cells, leukocytes, endothelial cells and epithelial cells. Moreover, soluble CD55 is detectable in plasma, tears, saliva, and urine, as well as in synovial and cerebrospinal uids [7] . Complement attack is a powerful innate mechanism in the protection of host against pathogens, including cancer. In recent years, several studies have demonstrated that CD55 expressed in clinical samples from various kinds of malignant tumors. CD55 expression level is higher in both di erentiated and undi erentiated gastric adenocarcinomas in comparison with normal gastric epithelium [8] . e staining intensity in prostatic carcinoma is also higher than in normal prostate epithelium. e knockeddown expression of CD55 reduces tumorigenicity of prostatic adenocarcinoma cell line in severe combined immunode cient mice [9] . Sakuma et al. found that CD55 expression in nonsmall cell lung cancer cells was closely correlated with histological types, prognosis and neoadjuvant chemotherapy of the disease [10] . ese ndings suggest that CD55 plays an important role in tumorigenicity of cancer cells.
Despite the importance of CD55 in other malignancies, its expression has not yet been analyzed in NPC. In order to clarify the role of CD55 in the pathogenesis of NPC, our study investigated the correlation of CD55 protein expression with clinicopathologic features, including patient survival.
Materials and Methods

Patients and Tissue Samples
is study was approved by the Research Ethics Committee of Department of Pathology of Southern Hospital, Southern Medical University, Guangzhou, China. Informed consent was obtained from all of the patients. All specimens were handled and made anonymous according to the ethical and legal standards.
Para n-embedded samples of 82 NPC tissues and 16 non-cancerous nasopharyngeal tissues were obtained under beroptic nasopharyngoscopy between 2000 and 2005 from the Department of Pathology of Southern Hospital. e control subjects were individuals presenting with otolaryngologicrelated, non-neoplastic diseases. In the 82 NPC cases, there were 58 male and 24 female patients, with ages ranging from 16 to 82 years (median, 49.5 years).
e routine staging workup included a detailed clinical examination of the head and neck, beroptic nasopharyngoscopy, computed tomography (CT) imaging of the entire neck from the base of the skull, chest radiography, abdominal sonography, a complete blood count and a biochemical pro le. All specimens had con rmed pathological diagnosis and were staged according to the 1997 NPC staging system of the WHO. None of the patients recruited in this study had chemotherapy or radiotherapy before the surgery. A er the surgery, all patients were treated with de nitive radiotherapy (cumulative dose of external beam radiotherapy ≥64.8 Gy). Patients whose tumor stages were ≥3 received additional cisplatin based concurrent chemoradiotherapy. For all enrolled patients, pathology records were retrieved from pathologic databases and medical records and reviewed for con rmation of the NPC diagnosis. Information on stage, treatment, follow-up and limited information on family history were collected from hospital tumor registries and medical les. e clinical and pathologic parameters were obtained from the pathological reports and presented in Table 1 .
Patients were followed-up at three month intervals during the rst three years a er therapy and at six month intervals therea er. e median follow-up time for overall survival was 60.8 months for patients, and ranged from 10 to 72 months. Patients who died from diseases other than NPC or from unexpected events were excluded from this study.
Immunohistochemistry analysis
Immunohistochemical study for CD55 was performed on formalin-xed, para n-embedded, 4 μm-thick tissue sections using the avidin-biotin-peroxidase complex method. In brief, the sections were depara nized and dehydrated using a graded series of ethanol solutions. Endogenous peroxidase activity was halted through the administration of 0.3% hydrogen peroxidase and methanol for 20 min. A er having been rinsed in phosphate-bu ered saline (PBS), the tissue sections were processed in a 0.01 M citrate bu er (pH 6.0) inside a heat-resistant plastic container. Sections were then irradiated in a domestic microwave oven for 20 min. A er microwave irradiation, the slides were allowed to cool at room temperature. e following antibody were applied as primary antibodies; rabbit anti-CD55 antibody (1: 35, sc-9156, Santa Cruz Biotechnologies, Santa Cruz, CA, USA). e sections were incubated with these primary antibodies overnight at 4°C followed by the secondary antibody. e results were visualized with diaminobenzidine. In each immunohistochemistry run, negative controls were carried out by omitting the primary antibody, whereas CD55 overexpression con rmed by western blotting was used as positive controls. Following a hematoxylin counterstaining, immunostaining was scored by two independent experienced pathologists, who were blinded to the clinicopathological parameters and clinical outcomes of the patients. e scores of the two pathologists were compared and any discrepant scores were trained through re-examining the stainings by both pathologists to achieve a consensus score. e number of positive-staining cells showing immunoreactivity on the membrane for CD55 in ten representative microscopic elds was counted and the percentage of positive cells was calculated. e percentage scoring of immunoreactive tumor cells was as follows: 0 (0%), 1 (1-10%), 2 (11-50%) and 3 (>50%). e staining intensity was visually scored and strati ed as follows: 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). A nal score was obtained for each case by multiplying the percentage and the intensity score. erefore, tumors with a multiplied score exceeding 4 (i.e.. tumors with a moderate or strong staining intensity of >10% of the tumor cells) were deemed to be positive expression of CD55; all other scores were considered to be negative.
Statistical analysis
SPSS version12.0 for Windows (SPSS Inc, IL, USA) and SAS 9.1 (SAS Institute, Cary, NC) was used for statistical analysis.
e association of the CD55 expression with the clinicopathological characteristics was analyzed using Χ 2 tests. Univariate survival analysis for the in uence of the CD55 expression on the overall survival was estimated according to the KaplanMeier method. e signi cances of various variables in survival were analyzed using multivariate cox proportional hazards model. Di erences were considered statistically signi cant when p was less than 0.05.
Results
Immuonohistochemical ndings of CD55
e expression levels and subcellular localization of CD55 protein in 82 archived para n-embedded NPC samples and 16 non-cancerous nasopharyngeal samples were detected using immunohistochemical staining. Speci c CD55 protein staining was found on the membrane of tumor cells ( Figure 1A) , whereas in the non-cancerous epithelial cells, CD55 staining was absent or only weakly positive ( Figure 1B) . Furthermore, in 80.5% (66/82) of NPC samples, CD55 protein was observed to be positive expressed. In comparison, only 31.3% (5/ 16) of non-cancerous nasopharyngeal samples had positively expressed CD55 protein, signi cantly lower than that in the NPC samples (p=0.003).
3. 
In uence of the CD55 expressions on survival
To investigate the prognostic value of CD55 expression for NPC, the association between the expression patterns of CD55 protein and patients' survival was assessed using KaplanMeier analysis using the log-rank test. In 82 NPC cases with prognosis information, the expression of CD55 protein was signi cantly correlated with the overall survival of NPC patients ( Figure 2 ). Patients with positive CD55 expression had poorer survival than those with negative CD55 expression (P=0.001). In addition, T, N, M classi cations and clinical stages were also signi cantly correlated with patients' survival (P=0.02, P<0.001, P=0.001, and P<0.001 respectively). To determine whether CD55 is an independent prognostic factor for NPC, multivariate analysis of the levels of CD55 protein expression, adjusted for age, gender, smoking status, T classication, N classi cation, M classi cation, and clinical stages of NPC patients, were performed. e results showed that the expression pattern of CD55 protein (P=0.009) was an independent prognostic factor for NPC (Table 2) .
Discussion
NPC is an endemic carcinoma in Southern China, Taiwan, and Southeast Asia. More than 70% of patients with the initial diagnosed NPC present with locally advanced-stage due to its deep location of tumor growth and vague symptoms at early stages [11] . stage with chemoradiotherapy is relatively good, there are still a fraction of patients who will develop regional relapse or distant metastasis a er treatment. erefore, it is necessary to search for simple and cost-e ective prognostic factors to establish risk-adapted treatment for NPC. In this study CD55 was found to be expressed predominantly in the NPC tissues by immunohistochemistry assay, which was consistent with other studies on prostate cancer, breast cancer and colon cancer [8] [9] [10] [12] [13] [14] . CD55 was also found to be overexpressed in NPC tissues compared with nasopharyngeal tissues, suggesting that CD55 is involved in the pathogenesis of NPC. e complement system provides a powerful means to control both pathogenic organisms and clearance of apoptotic cells. It is an enzymatic cascade consisting of 30 proteins found in plasma and on cell surfaces and three activation pathways, which results in the release of proin ammatory anaphylatoxins, in C3b deposition and in the formation of the membrane attack complex and nally leading to cell lysis [15] . CD55 is one of the complement regulatory proteins that binds to C3 convertases of both the classical and alternative complement pathways and protects cells against bystander attack from complement. It is composed of four external small consensus repeats and is glycosylphosphatidylinisotol (GPI)-anchored to the cell membrane [16] . Recently, CD55 has been shown to be deposited in the tumor microenvironment, to contribute to metastasis and to play an important role in tumorigenesis [17] [18] . In vitro, colorectal tumor cell lines expressing CD55 and endothelial cells deposit CD55 into the extracellular matrix [19] . is has already been detected in many di erent malignancies, including colorectal cancer, gastric cancer, thyroid cancer, medullary thyroid cancer, malignant glioma, breast cancer, renal cancer, non-small cell lung cancer, ovarian cancer, cervical cancer and prostate cancer [8] [9] [10] [12] [13] [14] . CD55 has also been found in the metastases of colorectal carcinomas. Moreover, studies have shown that it is frequently overexpressed within the stroma of colorectal tumors, suggesting that CD55 comes from the tumor cells and is either released from the cell membrane into the environment by enzymatic cleavage or is secreted by the tumor cells as a soluble peptide [20] . Recently, the expression of CD55 has been demonstrated as an essential requisite for cancer development and progression came from studies on prostate cancer cells in vitro and in vi o [21] . In this study, CD55 overexpression was signi cantly associated with N classi cation (lymph node metastasis), M classi cation (distant metastasis) and clinical stages of NPC patients. Overexpressed CD55 in NPC may accelerate tumor growth by inducing angiogenesis and enhancing local cell invasion and metastasis. Our results indicate that CD55 plays a signi cant role in NPC progression, including tumor invasion and metastasis. Yet, due to our limited sample size, with only four patients with distant metastatic disease, the observed association of CD55 with NPC metastasis should be veri ed by further studies.
CD55 is expressed by cells to protect them from bystander attack by complement, but it has been shown that the presence of even a small population of cells strongly expressing CD55 is a poor prognostic factor in a series of cancers. For example, Ikeda et al. reported that strong CD55 expression is su cient to predict poor prognosis in patients with breast cancer [22] . In contrast, Madjd et al. reported that loss of CD55 expression in breast cancer is associated with a worse prognosis [23] . In colorectal cancer, Durrant et al. prospectively analyzed the correlation between CD55 expression and seven year survival in 136 patients, and found that patients with tumors expressing high levels of CD55 had a signi cantly worse survival than patients with low CD55 levels [24] . In the present study, CD55 protein expression in NPC was found to be inversely correlated with patients' overall survival: the patients with positive expression of CD55 protein had shorter survival times. According to multivariate analyses, increased expression of CD55 protein was a signi cant predictor of poor prognosis for NPC patients, especially for patients with late-stage cancers.
ese results were analogous to recent reports on other malignancies.
In conclusion, our data shows that a subset of patients with NPC had upregulation of CD55, which was associated with an aggressive clinical course and poor overall survival, and was consistent with studies on other cancers. is is the rst report to suggest a relationship between CD55 expression and prognosis in patients with NPC, and further prospective analysis is warranted.
